Q-omics provides the consensus-scored NDUFA11 profile across patient tissues and cancer cell-line models. NDUFA11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NDUFA11 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, NDUFA11 protein abundance shows 18,824 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where NDUFA11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA11 survival associations across molecular data types. NDUFA11 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA11 RNA expression–survival associations across cancer types. High NDUFA11 expression shows unfavorable associations in ACC, KICH, UCS and UVM, but favorable associations in UCEC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NDUFA11 RNA expression.
This table summarizes NDUFA11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA11 shows higher tumor expression in LIHC, COAD, LUSC, KIRP, CHOL and ESCA. The LIHC box plot shows higher NDUFA11 RNA expression in tumor versus normal tissue (log2 FC = +0.742, t-test p < 0.001).
This table shows molecular features associated with NDUFA11 in patient tissues and cancer cell lines. In patient samples, NDUFA11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
